Pfizer C4471001 (BRAF V600): Solid Tumors - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out what the safest and most effective dose of the study drug (PF-07284890) is when given alone or in combination with Binimetinib.

What is the Condition Being Studied?

Advanced solid tumors (including primary brain)

Who Can Participate in the Study?

Adults with BRAF V600 mutant advanced solid tumors with and without brain involvement.

Age Group
Adults

What is Involved?

If you choose to join this study you will:
-Take the study drug (PF-07284890) by mouth 1 to 2 times a day
-Have a full eye examination
-Have physical exams, blood and urine tests.
-Have imaging scans (CT and/or MRI)

Some people will also:
-Take Binimetinib by mouth 2 times a day

Study Details

Full Title
A Two-Part, Phase 1a/b, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy of PF-07284890 (ARRY-461) in Participants with BRAF V600-Mutant Solid Tumors With and Without Brain Involvement
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00106594
NCT: NCT04543188
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698